Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

about

Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine heman Revisiting the IGF-1R as a breast cancer target.

P2860

Q38758443-86127C47-048D-4204-B18C-769C879C69F1 Q52686152-67079510-BEA5-4D23-AF46-38F2C71D0541

P2860

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

Item

http://www.wikidata.org/entity/Q40606069

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Preclinical Effectiveness of S ...... 57 in Osteosarcoma Cell Lines.

@en

type

Item

label

Preclinical Effectiveness of S ...... 57 in Osteosarcoma Cell Lines.

@en

prefLabel

Preclinical Effectiveness of S ...... 57 in Osteosarcoma Cell Lines.

@en

P1476

Preclinical Effectiveness of S ...... 157 in Osteosarcoma Cell Lines

@en

P2093

Hadas Reunevi

http://www.w3.org/2001/XMLSchema#string

P2860

Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein

The IRS-signalling system: a network of docking proteins that mediate insulin action

Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Critical nodes in signalling pathways: insights into insulin action

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FENDO.2015.00074

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Piero Picci

Katia Scotlandi

Cecilia Garofalo

Mariantonietta Capristo

Caterina Mancarella

P577

2015-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277351771

http://www.w3.org/2001/XMLSchema#string

P698

26029165

http://www.w3.org/2001/XMLSchema#string

P932

4429561

http://www.w3.org/2001/XMLSchema#string

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

about

P2860

P2860

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932